Serum Krebs von den Lungen-6 Level as a Reflecting Biomarker in Patients with Interstitial Lung Abnormalities

Hyung Koo Kang; Sung Jun Chung; Jiyeon Kang; Hyeon-Kyoung Koo; Sung-Soon Lee; Jae-Woo Jung; Jae-Chol Choi; Jae Yeol Kim; Jong Wook Shin

doi:10.4046/trd.2025.0134

Tuberc Respir Dis > Volume 89(2); 2026 > Article

Kang, Chung, Kang, Koo, Lee, Jung, Choi, Kim, and Shin: Serum Krebs von den Lungen-6 Level as a Reflecting Biomarker in Patients with Interstitial Lung Abnormalities

Original Article

Interstitial Lung Disease

Tuberculosis and Respiratory Diseases 2026;89(2):266-274.

Published online: December 17, 2025

DOI: https://doi.org/10.4046/trd.2025.0134

Serum Krebs von den Lungen-6 Level as a Reflecting Biomarker in Patients with Interstitial Lung Abnormalities

Hyung Koo Kang¹

, Sung Jun Chung¹, Jiyeon Kang¹, Hyeon-Kyoung Koo¹, Sung-Soon Lee¹, Jae-Woo Jung², Jae-Chol Choi², Jae Yeol Kim², Jong Wook Shin²

¹Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Republic of Korea

²Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Republic of Korea

Address for correspondence Jong Wook Shin Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, 102 Heukseok-ro, Dongjak-gu, Seoul 06973, Republic of Korea E-mail basthma@gmail.com

Received August 8, 2025 Revised November 21, 2025 Accepted December 16, 2025

It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/).

Abstract

Background

Research on the relationship between the progression of interstitial lung abnormalities (ILA) and serum biomarkers, including white blood cell differential counts and Krebs von den Lungen-6 (KL-6), is limited. This study aimed to examine the clinical characteristics of patients with ILA and evaluate the association between disease progression and serum biomarkers.

Methods

This retrospective cohort study analyzed data from 159 patients (63 with ILA and 74 with interstitial lung diseases) between October 2021 and September 2022. Data collected included clinical characteristics, pulmonary function tests, chest computed tomography (CT), complete blood cell counts, and KL-6 levels. In 52 of these patients who had previously undergone chest CT, the utility of serum biomarkers in reflecting radiologic progression was assessed using receiver operating characteristic curve analysis.

Results

Patients with ILA exhibited clinical characteristics similar to those with idiopathic pulmonary fibrosis. Serum KL-6 levels did not correlate with forced vital capacity or diffusing capacity of the lung for carbon monoxide in patients with ILA. Among the 52 patients with ILA, 13 demonstrated radiologic progression. Serum KL-6 displayed moderate predictive performance, with area under the curves ranging from 0.57 to 0.89 (p=0.014) for radiologic progression. Levels of KL-6 greater than 400 U/mL were more frequently observed in patients with radiologic progression (61.5% vs. 20.5%, p=0.006). In multivariate analysis, age and KL-6 were independently associated with radiologic progression in patients with ILA.

Conclusion

Serum KL-6 levels may serve as a potential indicator of ILA progression in asymptomatic patients. Those with KL-6 levels exceeding 400 U/mL should be closely monitored for radiologic progression.

Keywords: Interstitial Lung Abnormalities; KL-6; Interstitial Lung Disease; Progression

Introduction

Interstitial lung disease (ILD) is a diverse group of inflammatory and fibrotic conditions, with fibrotic ILD representing a significant subset that poses a major global health challenge [1]. Several fibrotic ILDs, including idiopathic pulmonary fibrosis (IPF), can lead to progressive declines in lung function, respiratory symptoms, and overall quality of life [2]. Fibrosis is characterized by recurrent, subclinical epithelial injury combined with accelerated epithelial aging, resulting in architectural distortion, irreversible loss of function, and early mortality [3]. Interstitial lung abnormalities (ILA) are defined as non-dependent findings on chest computed tomography (CT) that may indicate ILD in patients who do not have a clinical suspicion of the condition [4]. They are common incidental findings on CT, with a prevalence of 2% to 10% [4-6] and a progression rate of 20% to 72% in imaging [7-9]. According to imaging patterns, ILA is classified into nonsubpleural, subpleural nonfibrotic, and subpleural fibrotic types [4]. Though advanced age and copies of the mucin 5B (MUC5B) genotype are associated with imaging progression [7], little is known about the relationship between imaging progression and serum biomarkers, including white blood cell differential counts and Krebs von den Lungen-6 (KL-6), in ILA. Serum KL-6 is a circulating, high molecular weight glycoprotein expressed by type II pneumocytes. Its levels increase during the regeneration of type II pneumocytes and the destruction of the air-blood barrier in affected lungs [10]. Serum KL-6 has been reported as a sensitive marker for diagnosing and predicting the prognosis of ILD [11-13]. Although the pathophysiology of fibrotic ILD is not yet fully understood, various immune cells, such as monocytes, neutrophils, and lymphocytes, have been linked to its pathogenesis [14]. Several studies have demonstrated that serum monocyte count is a simple and cost-effective prognostic biomarker in patients with ILD [14-16]. However, few studies have examined serum biomarkers in patients with ILA. In this study, we aimed to explore the clinical characteristics of ILA in comparison to ILDs. Given that ILA may be associated with the early stages of progressive pulmonary fibrosis, including IPF, we also sought to determine whether serum biomarkers, such as KL-6 and white blood differential cell counts, correlate with imaging progression in patients with ILA.

Materials and Methods

1. Patients

In this observational cohort study, we retrospectively reviewed the medical records of 159 patients who underwent blood tests, including KL-6, and chest CT at a teaching hospital from October 2021 to September 2022. After excluding seven patients with unilateral abnormalities on chest CT and pneumonia, we analyzed the records of 64 patients with ILA and 88 patients with ILD. All patients with ILA presented to the hospital for a medical checkup with CT abnormalities, but without any symptoms or signs. Based on imaging patterns, the 64 patients with ILA were categorized into nonsubpleural, subpleural nonfibrotic, and subpleural fibrotic patterns [4]. Previous studies have indicated a higher risk of radiologic progression in subpleural ILA [17]. Consequently, we included 32 patients with subpleural nonfibrotic ILA and 31 patients with subpleural fibrotic ILA. Out of 88 patients with ILD, 14 were excluded due to small sample sizes. This group included eight patients with idiopathic interstitial pneumonia with autoimmune features, three with unclassifiable idiopathic interstitial pneumonia, one with cryptogenic organizing pneumonia, one with chronic hypersensitivity pneumonitis, and one with pleuroparenchymal fibroelastosis. Ultimately, 54 patients with IPF and 20 with connective tissue disease-associated ILD (CTD-ILD) were included (Figure 1).

Patient medical records were reviewed to gather data on medical conditions, pulmonary function tests, laboratory findings, and chest CT images. All patients included in the analysis underwent blood tests, including complete blood cell counts and KL-6, as well as a chest CT. Among the 63 patients with ILA, 53 had previously undergone chest CT more than 12 months prior and were enrolled to assess radiologic progression, as all patients had chest CT scans at the time of enrollment. Although the specific duration of radiologic progression in ILA is not clearly defined, the criteria for progressive pulmonary fibrosis typically involve a 1-year timeframe [18]. Due to the retrospective nature of this study, chest CT scans performed exactly 1 year after diagnosis were not always available. Therefore, we included patients who had follow-up CT scans obtained within 18 months. One patient who had undergone a chest CT more than 36 months prior was excluded. Since none of the patients without radiologic progression showed improvements, all patients with chest CT scans taken more than 1 year apart were included. For patients with radiologic progression, we used the chest CT obtained within 12 months (up to a maximum of 18 months). For those without progression, we selected the most recent CT scan taken approximately 12 months after diagnosis. In total, 52 patients were analyzed for radiologic progression in this study.

The Institutional Review Board of Inje University Ilsan Paik Hospital approved this study, including the review and publication of information obtained from patient records (IRB no. 2022-09-044). The requirement for informed consent was waived for the use of patient medical data, as all patient information was anonymized and de-identified prior to analysis.

2. Measurement

Demographic features, smoking history, and comorbidities were obtained by reviewing the available medical records on the day the patients underwent laboratory tests. Diagnoses of IPF and CTD-ILD were established through a multidisciplinary approach in accordance with diagnostic guidelines [18,19]. Comorbidities were reviewed, including hypertension, diabetes mellitus, ischemic heart disease, chronic obstructive pulmonary disease (COPD), and emphysema. Emphysema was confirmed through chest CT.

CT scans were obtained using a 320-detector row CT scanner (Aquilion ONE/PRIME SP; Canon Medical Systems, Otawara, Japan). ILA are defined by incidental CT findings of non-dependent abnormalities, according to the Fleischner position paper [4]. These findings include ground-glass or reticular abnormalities, lung distortion, traction bronchiectasis, honeycombing, and non-emphysematous cysts [4]. ILA was categorized into subpleural nonfibrotic and fibrotic ILA based on the presence of pulmonary fibrosis, characterized by architectural distortion, traction bronchiectasis, or honeycombing [4]. Radiologic progression was defined as an increased extent of fibrotic features—such as traction bronchiectasis, ground-glass opacity, reticulation, and honeycombing— on chest CT imaging obtained at enrollment compared to previous chest CT imaging [18].

In our analysis, we did not include features like non-dependent ground-glass opacities or centrilobular nodularity in the definition of progression. This progression was assessed independently by one pulmonologist and one radiologist. We evaluated inter-observer agreement for key radiologic features using the kappa statistic. In cases of disagreement, both readers reviewed the images together to reach a consensus.

Spirometry was performed following the official guidelines of the American Thoracic Society [20]. The absolute values of forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (DL_CO) were obtained, and the percentage of predicted values (% predicted) for both FVC and DL_CO was calculated using equations derived from a representative Korean sample [21].

Medical records of blood tests, including complete blood count and KL-6 levels, were collected. We included only patients who had both chest CT and serum biomarker measurements available within a 2-week window. Neutrophil, lymphocyte, and monocyte counts, as well as the neutrophil-lymphocyte ratio (NLR), were calculated from the complete blood count results. The threshold for stratifying patients by monocyte count was set at 600 cells/μL [14]. Serum KL-6 levels were measured using the Nanopia KL-6 assay (Sekisui Diagnostics, Tokyo, Japan). While the manufacturers recommend a cutoff value of 500 U/mL for the KL-6 assay, we used 400 U/mL based on the results of the receiver operating characteristic (ROC) curves conducted in this study.

3. Statistical analysis

Data are presented as medians and interquartile ranges (IQRs) for continuous variables, and as counts (%) for categorical variables. Continuous variables were compared using the Mann-Whitney U test, while categorical variables were analyzed using either Pearson’s chi-square test or Fisher’s exact test. To evaluate the relationship between serum biomarkers and FVC in patients with ILA and IPF, Spearman’s correlation and a linear model were employed. ROC curves were generated for KL-6, neutrophils, lymphocytes, monocytes, and NLR to assess each biomarker's ability to discriminate radiologic progression, with varying thresholds for each variable. The areas under the ROC curves (AUC) were calculated and compared. Additionally, multivariate logistic regression analysis was conducted to identify independent factors associated with radiologic progression in patients with ILAs. A statistical p-value of <0.05 was deemed significant. All analyses were performed using IBM SPSS Statistics for Windows version 22.0 (IBM Corp., Armonk, NY, USA).

Results

1. Baseline characteristics of study patients compared with IPF

The clinical characteristics of the study participants are summarized in Table 1. Among the 63 patients with ILA, 60 (95.2%) were men, 11 (17.5%) were lifetime nonsmokers, and the median age was 74 years (IQR, 69 to 78). Of these patients, 22 (34.9%) had been diagnosed with ischemic heart disease, and 18 (29%) had COPD. In the ILA cohort, age, sex, smoking history, and comorbidities were significantly different compared to patients with CTD-ILD, but not with those with IPF (Supplementary Table S1).

For patients with ILA, the median FVC (% predicted) and DL_CO (% predicted) were 94% (IQR, 85% to 104%) and 85% (IQR, 74% to 99%), respectively. The median white blood cell count (cells/μL), neutrophil count (cells/μL), monocyte count (cells/μL), and KL-6 level (U/mL) were 6,790/μL (IQR, 5,555 to 7,500), 3,762/μL (IQR, 2,981 to 4,510), 518/μL (IQR, 420 to 604), and 331.0 U/mL (IQR, 251.7 to 431.1), respectively. These values were significantly lower than those observed in patients with IPF (Figure 2). Monocyte counts greater than 600/μL were less frequent in patients with ILA compared to those with IPF. Serum biomarkers were not associated with FVC or DL_CO in patients with ILA, while KL-6 exhibited significant negative correlations with both measures in IPF, and no meaningful correlations were observed for other biomarkers (Supplementary Table S2).

2. Characteristics of ILA according to radiologic progression

A total of 52 patients with ILA were divided into two groups: those with radiologic progression (n=13) and those without (n=39). The baseline characteristics, pulmonary functions, complete blood cell counts, and ILA types were not significantly different between the two groups (Table 2). Notably, elevated KL-6 levels (>400 U/mL) were significantly more common in patients with radiologic progression (61.5% vs. 20.5%, p=0.006).

3. Factors associated with radiologic progression of ILAs

Candidate variables for logistic regression analysis included DL_CO (% predicted), KL-6 >400 U/mL, and subpleural fibrotic ILA. These objective variables had p<0.1 in the comparison between ILA patients with and without radiologic progression, along with age, sex, and smoking status (Table 3). In the multivariate analysis, age (adjusted odds ratio [aOR], 1.16; 95% confidence interval [CI], 1.01 to 1.34; p=0.039) and KL-6 >400 U/mL (aOR, 8.32; 95% CI, 1.46 to 47.32; p=0.017) were independently associated with radiologic progression.

4. The performance of biomarkers in reflecting the radiologic progression of ILA

The overall performance of biomarkers, including KL-6, NLR, lymphocytes, neutrophils, and monocytes, in reflecting radiologic progression over 12 to 18 months was evaluated by constructing ROC curves (Figure 3). The AUC of the ROC curves were as follows: 0.730 for KL-6 (95% CI, 0.571 to 0.888; p=0.014), 0.560 for NLR (95% CI, 0.359 to 0.762; p=0.519), 0.394 for lymphocytes (95% CI, 0.208 to 0.581; p=0.258), 0.473 for neutrophils (95% CI, 0.275 to 0.672; p=0.775), and 0.458 for monocytes (95% CI, 0.227 to 0.638; p=0.650). When the threshold value from the ROC analysis was set at 400 U/mL for serum KL-6, the sensitivity, specificity, positive predictive value, and negative predictive value were 61.5%, 79.5%, 50.0%, and 86.1%, respectively.

Discussion

In the present study, we found that patients with ILAs exhibited clinical characteristics similar to those seen in IPF, rather than in CTD-ILD. We also demonstrated that serum KL-6 levels were associated with radiologic progression over 12 to 18 months in asymptomatic patients with ILA, but were not correlated with pulmonary function in these patients, which contrasts with findings in IPF and CTD-ILD. Furthermore, we found that KL-6 levels greater than 400 U/mL were linked to radiologic progression in patients with ILA. White blood cell differential counts—including neutrophils, lymphocytes, the NLR, and monocytes—were not significantly associated with pulmonary function or radiologic progression in patients with ILA. ILA is defined as an incidental CT finding of non-dependent abnormalities occurring in the absence of clinical respiratory symptoms [4]. Identifying the early stages of an undiagnosed form of progressive ILD is an important challenge in asymptomatic patients with ILA [22]. A cohort study has shown that the histopathologic features of ILA represent an early stage and mild form of pulmonary fibrosis in some cases. Specifically, ILA with subpleural radiologic features is associated with histopathological findings of usual interstitial pneumonia [23]. Additionally, the subpleural fibrotic pattern is linked to the highest risk of progression [7]. In our study, while subpleural fibrotic ILA is not significantly associated with radiologic progression, a tendency was observed linking subpleural fibrotic ILA to radiologic progression.

Serum KL-6 is classified as a human MUC1 mucin protein, with regenerating type 2 pneumocytes serving as the primary cellular source of KL-6/MUC1 in the lungs of patients with ILD [24]. It is significantly elevated in patients with ILD due to increased expression by regenerating type 2 pneumocytes and heightened permeability following damage to the alveolocapillary barriers in the lungs [25]. Previous studies have shown that serum KL-6 correlates with lung function and radiologic parameters, including the extent of fibrotic abnormalities in patients with ILD [26,27]. Additionally, they demonstrated that the serum KL-6 level at the time of diagnosis predicts the progression and acute exacerbation of ILD [28-31].

In this study, our data from patients with ILA revealed that serum KL-6 levels were not linked to pulmonary function but were associated with radiologic progression. Specifically, we found that KL-6 levels exceeding 400 U/mL correlated with radiologic progression within 12 to 18 months. The lack of association between serum KL-6 and pulmonary function may be attributed to our focus on asymptomatic patients with ILA, who generally exhibited relatively normal lung function compared to those with IPF and CTD-ILD. Nevertheless, our findings provide significant insights into the radiologic progression of ILA.

Previous studies have shown that immune-related cells, such as monocytes, neutrophils, and lymphocytes, may serve as potential cellular biomarkers for disease progression. This aligns with existing knowledge about the roles of monocytes and other immune cells in the development of ILD [14,16,32,33].

Our study found that white blood cell differential counts—specifically neutrophils, lymphocytes, and monocytes—were not associated with radiologic progression in patients with idiopathic lung disease (ILA). The white blood cell count serves as a nonspecific marker of inflammation or immune response. Asymptomatic patients with ILA may not experience disease progression due to minimal inflammation. The strength of our study lies in the evaluation of serum biomarkers, including KL-6 and white blood cell differential counts, as prognostic factors in asymptomatic patients with ILA, an approach previously explored only in patients with ILD. Additionally, we consistently assessed chest CT imaging using uniform criteria at a single institution. Although the Fleischner Society [4] defined the criteria for ILA, a skilled physician specializing in this area conducted a thorough review of the images using standardized criteria. This aspect can yield more reliable and consistent data.

The present study has several limitations. First, due to its retrospective observational design, there is a possibility that selection bias or confounding factors may have influenced our findings. This design also restricts our ability to assess serum biomarkers as prognostic indicators. Second, we were unable to evaluate a healthy control group without ILA or ILD. Future prospective studies comparing patients with ILA to healthy controls would provide valuable insights into the utility of KL-6 in this population. Nonetheless, our study does highlight differences in the clinical use of serum KL-6 between patients with ILA and those with ILD. Third, the small sample size limits our ability to identify risk factors for radiologic progression. Despite this limitation, we were able to demonstrate a significant association between KL-6 levels and radiologic progression. Finally, since blood samples were not collected for this study, we could not assess other systemic biomarkers, such as matrix metalloproteinase 7, surfactant protein D, and chemokine ligand 18. Further research exploring the relationships between these systemic biomarkers and radiologic progression would be beneficial for identifying risk factors associated with progression.

In conclusion, this study demonstrated that serum KL-6 may serve as a predictive marker for imaging progression within 12 to 18 months in patients with ILA. Additionally, the ROC-derived threshold value of KL-6 for radiologic progression was found to be 400 U/mL. These results highlight the importance of careful monitoring, as a KL-6 level exceeding 400 in asymptomatic patients with ILA.

Notes

Authors’ Contributions

Conceptualization: Kang HK, Shin JW. Methodology: Kang HK, Koo HK, Jung JW, Choi JC, Kim JY, Shin JW. Formal analysis: Kang HK, Shin JW. Data curation: Kang HK, Chung SJ, Kang J, Koo HK, Lee SS, Shin JW. Project administration: Kang HK, Koo HK, Jung JW, Choi JC, Kim JY, Shin JW. Software: Kang HK. Validation: Kang HK, Koo HK, Shin JW. Investigation: Kang HK. Writing - original draft preparation: Kang HK. Writing - review and editing: all authors. Approval of final manuscript: all authors.

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

Funding

This work was supported by a grant from research year of Inje University in 2022 (20220021).

Supplementary Material

Supplementary material can be found in the journal homepage (http://www.e-trd.org).

Supplementary Table S1.

Baseline characteristics of patients with ILAs and CTD-ILD.

trd-2025-0134-Supplementary-Table-S1.pdf

Supplementary Table S2.

Association between serum biomarkers and pulmonary function parameters in patients with ILAs and IPF.

trd-2025-0134-Supplementary-Table-S2.pdf

Fig. 1.

Study population. KL-6: Krebs von den Lungen-6; ILA: interstitial lung abnormality; ILD: interstitial lung disease; IPAF: interstitial pneumonia with autoimmune feature; IIP: idiopathic interstitial pneumonia; COP: cryptogenic organizing pneumonia; HP: hypersensitivity pneumonitis. PPFE: pleuroparenchymal fibroelastosis; IPF: idiopathic pulmonary fibrosis; CTD-ILD: connective tissue disease-associated interstitial lung disease.

Fig. 2.

Comparison of serum biomarkers between interstitial lung abnormality (ILA) and idiopathic pulmonary fibrosis (IPF). (A) Blood cell counts including white blood cells (WBCs), neutrophil, lymphocyte, and monocyte. (B) Serum Krebs von den Lungen-6 (KL-6). NEU: neutrophil; LYM: lymphocyte; MO: monocyte; IQR: interquartile range.

Fig. 3.

Receiver operating characteristic (ROC) curves of radiologic progression and biomarkers in patients with interstitial lung abnormalities. KL-6: Krebs von den Lungen-6; AUC: area under the ROC curve; CI: confidence interval.

Table 1.

Baseline characteristics of patients with ILAs and IPF

Characteristic	ILA (n=63)	IPF (n=54)	ILA vs. IPF p-value
Age, yr	74 (69-78)	75 (69-80)	0.599
Men	60 (95.2)	50 (92.6)	0.548
Body mass index, kg/m²	24.0 (22.4-26.0)	24.0 (22.4-26.2)	0.445
Lifetime nonsmoker	11 (17.5)	8 (14.8)	0.671
Smoking, pack-yr	40 (10-50)	30 (20-40)	0.476
Comorbidity
Hypertension	28 (44.4)	28 (51.9)	0.424
Diabetes mellitus	11 (17.5)	19 (35.2)	0.029
Ischemic heart disease	22 (34.9)	15 (27.8)	0.408
COPD	18 (29.0)	6 (11.1)	0.092
Emphysema	28 (44.4)	20 (37.0)	0.417
Pulmonary function
FVC, L	3.34 (2.90-3.78)	2.65 (2.19-3.14)	<0.001
FVC, % predicted	94 (85-104)	77 (69-93)	<0.001
DL_CO, mL/mm Hg/min	13.7 (11.0-16.0)	9.2 (7.0-10.5)	<0.001
DL_CO, % predicted	85 (74-99)	59 (48-64)	<0.001
Laboratory findings
White blood cells, /μL	6,790 (5,555-7,500)	7,550 (6,020-9,202)	<0.001
Neutrophil, /μL	3,762 (2,981-4,510)	4,541 (3,613-5,955)	<0.001
Lymphocyte, /μL	2,070 (1,683-2,415)	2,006 (1,640-2,593)	0.571
NLR	1.69 (0.97-2.55)	2.35 (1.68-2.70)	0.090
Monocyte, /μL	518 (420-604)	599 (473-719)	0.037
Monocyte >600/μL	16 (25.4)	27 (62.8)	0.006
KL-6, U/mL	331.0 (251.7-431.1)	775.7 (503.5-1,144.1)	<0.001

Values are presented as median (interquartile range) or number (%).

ILA: interstitial lung abnormality; IPF: idiopathic pulmonary fibrosis; COPD: chronic obstructive pulmonary disease; FVC: forced vital capacity; DL_CO: carbon monoxide diffusion capacity; NLR: neutrophil-lymphocyte ratio; KL-6: Krebs von den Lungen-6.

Table 2.

Baseline characteristics of 52 patients with ILAs according to radiologic progression

Characteristic	ILA without radiologic progression (n=39)	ILA with radiologic progression (n=13)	p-value
Age, yr	74 (68-76)	79 (72-80)	0.403
Men	37 (94.9)	12 (92.3)	0.731
Body mass index, kg/m²	23.3 (22.1-25.9)	24.3 (23.0-27.0)	0.951
Lifetime nonsmoker	9 (23.7)	2 (15.4)	0.530
Smoking, pack-yr	40 (10-50)	30 (10-50)	0.479
Comorbidity
Hypertension	16 (41.0)	7 (53.8)	0.832
Diabetes mellitus	7 (17.9)	2 (15.4)	0.697
Ischemic heart disease	12 (30.8)	5 (38.5)	0.609
COPD	10 (25.6)	4 (30.8)	0.718
Emphysema	18 (46.2)	5 (38.5)	0.629
Pulmonary function
FVC, L	3.30 (2.88-3.89)	3.38 (3.02-3.78)	0.467
FVC, % predicted	94.5 (84.8-105.5)	92.0 (85.0-108.0)	0.703
DL_CO, mL/mm Hg/min	14.3 (10.8-17.6)	11.8 (9.9-13.9)	0.297
DL_CO, % predicted	85 (75-102)	79 (64-87)	0.087
Laboratory findings
White blood cells, /μL	6,800 (5,500-7,490)	6,740 (5,505-7,675)	0.680
Neutrophil, /μL	3,075 (2,940-4,502)	4,389 (2,734-5,554)	0.945
Lymphocyte, /μL	2,138 (1,818-2,673)	2,070 (1,308-2,176)	0.337
NLR	1.67 (1.18-2.09)	2.00 (1.38-3.50)	0.349
Monocyte, /μL	571 (441-612)	513 (368-584)	0.418
Monocyte >600 /μL	11 (28.2)	3 (23.1)	0.718
KL-6, U/mL	294 (230-390)	396 (301-719)	0.534
KL-6 > 400 U/mL	8 (20.5)	8 (61.5)	0.006
CT follow-up interval, mo	18 (12-24)	12 (12-16.5)	0.877
Subpleural fibrotic ILA	16 (41.0)	9 (69.2)	0.078

Values are presented as median (interquartile range) or number (%).

ILA: interstitial lung abnormality; COPD: chronic obstructive pulmonary disease; FVC: forced vital capacity; DL_CO: carbon monoxide diffusion capacity; NLR: neutrophil-lymphocyte ratio; KL-6: Krebs von den Lungen-6; CT: computed tomography.

Table 3.

Factors associated with radiologic progression of ILAs

Characteristic	Univariate		Multivariate
Characteristic	OR (95% CI)	p-value	OR (95% CI)	p-value
Age	1.10 (0.99−1.22)	0.057	1.16 (1.01−1.34)	0.039
Male	0.65 (0.05−7.8)	0.733	0.60 (0.15−23.73)	0.785
Lifetime nonsmoker	0.59 (0.11−3.15)	0.533	0.34 (0.03−3.77)	0.376
DL_CO, % predicted	0.97 (0.93−1.00)	0.062	0.98 (0.94−1.02)	0.264
KL-6 >400 U/mL	6.20 (1.59−24.18)	0.009	8.32 (1.46−47.32)	0.017
Subpleural fibrotic ILA	3.23 (0.85−12.35)	0.086	3.38 (0.59−19.27)	0.171

ILA: interstitial lung abnormality; OR: odds ratio; CI: confidence interval; DL_CO: carbon monoxide diffusion capacity; KL-6: Krebs von den Lungen-6.

REFERENCES

1. Spagnolo P, Ryerson CJ, Putman R, Oldham J, Salisbury M, Sverzellati N, et al. Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities. Lancet Respir Med 2021;9:1065-76.

2. Cottin V, Hirani NA, Hotchkin DL, Nambiar AM, Ogura T, Otaola M, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev 2018;27:180076.

3. Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med 2018;378:1811-23.

4. Hatabu H, Hunninghake GM, Richeldi L, Brown KK, Wells AU, Remy-Jardin M, et al. Interstitial lung abnormalities detected incidentally on CT: a position paper from the Fleischner Society. Lancet Respir Med 2020;8:726-37.

5. Putman RK, Hatabu H, Araki T, Gudmundsson G, Gao W, Nishino M, et al. Association between interstitial lung abnormalities and all-cause mortality. JAMA 2016;315:672-81.

6. Hoyer N, Wille MM, Thomsen LH, Wilcke T, Dirksen A, Pedersen JH, et al. Interstitial lung abnormalities are associated with increased mortality in smokers. Respir Med 2018;136:77-82.

7. Putman RK, Gudmundsson G, Axelsson GT, Hida T, Honda O, Araki T, et al. Imaging patterns are associated with interstitial lung abnormality progression and mortality. Am J Respir Crit Care Med 2019;200:175-83.

8. Tsushima K, Sone S, Yoshikawa S, Yokoyama T, Suzuki T, Kubo K. The radiological patterns of interstitial change at an early phase: over a 4-year follow-up. Respir Med 2010;104:1712-21.

9. Jin GY, Lynch D, Chawla A, Garg K, Tammemagi MC, Sahin H, et al. Interstitial lung abnormalities in a CT lung cancer screening population: prevalence and progression rate. Radiology 2013;268:563-71.

10. Cho EJ, Park KJ, Ko DH, Koo HJ, Lee SM, Song JW, et al. Analytical and clinical performance of the Nanopia Krebs von den Lungen 6 assay in Korean patients with interstitial lung diseases. Ann Lab Med 2019;39:245-51.

11. Kumanovics G, Gorbe E, Minier T, Simon D, Berki T, Czirjak L. Follow-up of serum KL-6 lung fibrosis biomarker levels in 173 patients with systemic sclerosis. Clin Exp Rheumatol 2014;32:S138-44.

12. Zheng P, Liu X, Huang H, Guo Z, Wu G, Hu H, et al. Diagnostic value of KL-6 in idiopathic interstitial pneumonia. J Thorac Dis 2018;10:4724-32.

13. Wang J, Zheng P, Huang Z, Huang H, Xue M, Liao C, et al. Serum SP-A and KL-6 levels can predict the improvement and deterioration of patients with interstitial pneumonia with autoimmune features. BMC Pulm Med 2020;20:315.

14. Kreuter M, Lee JS, Tzouvelekis A, Oldham JM, Molyneaux PL, Weycker D, et al. Monocyte count as a prognostic biomarker in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2021;204:74-81.

15. Teoh AK, Jo HE, Chambers DC, Symons K, Walters EH, Goh NS, et al. Blood monocyte counts as a potential prognostic marker for idiopathic pulmonary fibrosis: analysis from the Australian IPF registry. Eur Respir J 2020;55:1901855.

16. Achaiah A, Rathnapala A, Pereira A, Bothwell H, Dwivedi K, Barker R, et al. Monocyte and neutrophil levels are potentially linked to progression to IPF for patients with indeterminate UIP CT pattern. BMJ Open Respir Res 2021;8:e000899.

17. Leone PM, Richeldi L. Interstitial lung abnormalities a risk factor for rheumatoid arthritis interstitial lung disease progression: what's new. Breathe (Sheff) 2020;16:200223.

18. Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2022;205:e18-47.

19. Koo SM, Kim SY, Choi SM, Lee HK. Korean guidelines for diagnosis and management of interstitial lung diseases: part 5. connective tissue disease associated interstitial lung disease. Tuberc Respir Dis (Seoul) 2019;82:285-97.

20. Culver BH, Graham BL, Coates AL, Wanger J, Berry CE, Clarke PK, et al. Recommendations for a standardized pulmonary function report: an official American Thoracic Society technical statement. Am J Respir Crit Care Med 2017;196:1463-72.

21. Choi JK, Paek D, Lee JO. Normal predictive values of spirometry in Korean population. Tuberc Respir Dis 2005;58:230-42.

22. Hunninghake GM, Goldin JG, Kadoch MA, Kropski JA, Rosas IO, Wells AU, et al. Detection and early referral of patients with interstitial lung abnormalities: an Expert Survey Initiative. Chest 2022;161:470-82.

23. Miller ER, Putman RK, Vivero M, Hung Y, Araki T, Nishino M, et al. Histopathology of interstitial lung abnormalities in the context of lung nodule resections. Am J Respir Crit Care Med 2018;197:955-8.

24. Ishikawa N, Hattori N, Yokoyama A, Kohno N. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir Investig 2012;50:3-13.

25. Mostafa AI, Salem AE, Ahmed HA, Bayoumi AI, Halim RM, Samie RM. Role of Krebs von den Lungen-6 (KL-6) in assessing hypersensitivity pneumonitis. Tuberc Respir Dis (Seoul) 2021;84:200-8.

26. Sakamoto K, Taniguchi H, Kondoh Y, Johkoh T, Sumikawa H, Kimura T, et al. Serum KL-6 in fibrotic NSIP: correlations with physiologic and radiologic parameters. Respir Med 2010;104:127-33.

27. Qin H, Xu XP, Zou J, Zhao XJ, Wu HW, Zha QF, et al. Krebs von den Lungen-6 associated with chest high-resolution CT score in evaluation severity of patients with interstitial lung disease. Pulmonology 2019;25:143-8.

28. Kuwana M, Shirai Y, Takeuchi T. Elevated serum Krebs von den Lungen-6 in early disease predicts subsequent deterioration of pulmonary function in patients with systemic sclerosis and interstitial lung disease. J Rheumatol 2016;43:1825-31.

29. Jiang Y, Luo Q, Han Q, Huang J, Ou Y, Chen M, et al. Sequential changes of serum KL-6 predict the progression of interstitial lung disease. J Thorac Dis 2018;10:4705-14.

30. Wakamatsu K, Nagata N, Kumazoe H, Oda K, Ishimoto H, Yoshimi M, et al. Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis. Respir Investig 2017;55:16-23.

31. Kim HC, Choi KH, Jacob J, Song JW. Prognostic role of blood KL-6 in rheumatoid arthritis-associated interstitial lung disease. PLoS One 2020;15:e0229997.

32. Zinellu A, Paliogiannis P, Sotgiu E, Mellino S, Mangoni AA, Zinellu E, et al. Blood cell count derived inflammation indexes in patients with idiopathic pulmonary fibrosis. Lung 2020;198:821-7.

33. Karampitsakos T, Torrisi S, Antoniou K, Manali E, Korbila I, Papaioannou O, et al. Increased monocyte count and red cell distribution width as prognostic biomarkers in patients with Idiopathic Pulmonary Fibrosis. Respir Res 2021;22:140.

TOOLS

METRICS

1 Crossref
0 Scopus
960 View
57 Download

ORCID iDs

Hyung Koo Kang
https://orcid.org/0000-0001-9671-0944

Jong Wook Shin
https://orcid.org/0000-0002-4340-8458

Funding Information

Inje University
https://doi.org/10.13039/501100002636
20220021

Related articles

Serun Zinc Levels and Urinary Zinc Excretion in Patients with Lung Cancer1987 June;34(2)

Expression of Transforming Growth Factor-Beta in Patients with Interstitial Lung Diseases (ILD).1996 April;43(2)

ABOUT

ARTICLE & TOPICS

Article category

Browse all articles >

Topics

Browse all articles >

BROWSE ARTICLES

FOR CONTRIBUTORS

Editorial Office: 101-605, 58, Banpo-daero, Seocho-gu (Seocho-dong, Seocho Art-Xi), Seoul 06652, Korea
Tel: +82-2-575-3825, +82-2-576-5347 Fax: +82-2-572-6683 E-mail: katrdsubmit@lungkorea.org